Table 3. HBV-mediated pathway perturbation.
| Pathway | p-value at 48hr | p-value at 72hr |
|---|---|---|
| ECM-receptor interaction | 0.068 | < 0.001 |
| Central carbon metabolism in cancer | 0.167 | < 0.001 |
| Carbon metabolism | 0.143 | < 0.001 |
| Nitrogen metabolism | 0.434 | 0.001 |
| Butanoate metabolism | 0.538 | 0.002 |
| Metabolic pathways | 0.654 | 0.002 |
| Glycolysis / Gluconeogenesis | NA | 0.002 |
| PI3K-AKT signaling pathway | 0.038 | 0.002 |
| Biosynthesis of amino acids | 0.013 | 0.002 |
| Glycine, serine and threonine metabolism | 0.010 | 0.004 |
| Taurine and hypotaurine metabolism | NA | 0.004 |
| Bile secretion | 0.104 | 0.004 |
| Focal adhesion | 0.021 | 0.004 |
| Galactose metabolism | NA | 0.005 |
| Aminoacyl-tRNA biosynthesis | 0.244 | 0.006 |
| Arginine and proline metabolism | 0.563 | 0.006 |
| Hematopoietic cell lineage | 0.022 | 0.007 |
| Fructose and mannose metabolism | 0.666 | 0.007 |
| Amoebiasis | 0.691 | 0.009 |
| Glycosphingolipid biosynthesis | 0.306 | 0.009 |
| Glycosphingolipid biosynthesis | 0.410 | 0.009 |
| Glycosphingolipid biosynthesis | 0.410 | 0.009 |
| Drug metabolism | 0.539 | 0.010 |
| Calcium signaling pathway | 0.127 | 0.010 |
| Neuroactive ligand-receptor interaction | 0.168 | 0.012 |
| Tryptophan metabolism | NA | 0.013 |
| Small cell lung cancer | 0.086 | 0.017 |
| PPAR signaling pathway | 0.415 | 0.019 |
| Rap1 signaling pathway | 0.853 | 0.024 |
| Insulin secretion | 0.490 | 0.026 |
| Glycosphingolipid biosynthesis | 0.306 | 0.026 |
| Glycosphingolipid biosynthesis | 0.410 | 0.026 |
| Glycosphingolipid biosynthesis | 0.410 | 0.026 |
| Maturity onset diabetes of the young | 0.341 | 0.031 |
| Cytokine-cytokine receptor interaction | 0.570 | 0.033 |
| Retinol metabolism | 0.123 | 0.038 |
| Alanine, aspartate and glutamate metabolism | 0.083 | 0.040 |
| Inflammatory mediator regulation of TRP channels | 0.942 | 0.041 |
| Cholinergic synapse | 0.140 | 0.042 |
| Pathways in cancer | 0.033 | 0.043 |
| Glycosphingolipid biosynthesis | 0.306 | 0.043 |
| Glycosphingolipid biosynthesis | 0.410 | 0.043 |
| Glycosphingolipid biosynthesis | 0.410 | 0.043 |
| Butirosin and neomycin biosynthesis | NA | 0.045 |
| Cyanoamino acid metabolism | 0.150 | 0.045 |
| Valine, leucine and isoleucine biosynthesis | 0.150 | 0.045 |
| Glutathione metabolism | 0.244 | 0.046 |
| Vascular smooth muscle contraction | 0.179 | 0.048 |
| Protein digestion and absorption | 0.004 | 0.053 |
| Dilated cardiomyopathy | 0.044 | 0.111 |
| Hypertrophic cardiomyopathy (HCM) | 0.030 | 0.153 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 0.036 | 0.281 |
| MicroRNAs in cancer | < 0.001 | 0.339 |
| Fanconi anemia pathway | 0.010 | 0.460 |
| Bladder cancer | 0.028 | 0.520 |
| p53 signaling pathway | 0.007 | 0.738 |
*NA indicates genes within that pathway were not identified as significantly altered in this at this time point
*Bold indicates pathways that are significantly perturbed in both comparisons